Deborah Keller

Laboratory Corporation of America has named Deborah Keller as the CEO of Covance Drug Development. She takes over for Joseph Herring who will retire on July 31 after more than a decade as CEO.

Keller joined Covance in 1987 and has held senior leadership roles in global operations, quality assurance, and marketing. Most recently she served as executive vice president of Covance and group president of R&D Laboratories where she led more than 6,000 employees at 18 facilities across the globe.  

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.